The roles of UVB and vitamin D in reducing risk of cancer incidence and mortality: A review of the epidemiology, clinical trials, and mechanisms

Reviews in Endocrine and Metabolic Disorders

Volumn 18, Issue 2, 2017, Pages 167-182

  Moukayed, Meis ^a   Grant, William B ^b  

^a AMERICAN UNIVERSITY IN DUBAI   (United Arab Emirates)

^b Sunlight   (United States)

Author keywords

Breast; Cancer; Clinical trials; Colorectal; Epidemiology; Incidence; Lung; Mechanisms; Ovarian; Pancreatic; Prevention; Prostate; Risk; Ultraviolet B; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; VITAMIN D;

ADJUVANT THERAPY; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DRUG MECHANISM; HUMAN; LUNG CANCER; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; REVIEW; ULTRAVIOLET B RADIATION; VITAMIN METABOLISM; VITAMIN SUPPLEMENTATION; INCIDENCE; MALE; MORTALITY; NEOPLASM; PHYSIOLOGY; PROCEDURES; RISK FACTOR; STATISTICS AND NUMERICAL DATA; SUNLIGHT; ULTRAVIOLET RADIATION;

CLINICAL TRIALS AS TOPIC; HUMANS; INCIDENCE; MALE; NEOPLASMS; RISK FACTORS; SUNLIGHT; ULTRAVIOLET RAYS; VITAMIN D;

EID: 85013104442     PISSN: 13899155     EISSN: 15732606     Source Type: Journal    
DOI: 10.1007/s11154-017-9415-2     Document Type: Review

References (150)

1. GLOBOCAN. 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. International Agency for Research on Cancer: World Health Organization; 2016.
2. Global, Regional, and National life Expectancy. All-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459–544. doi:10.1016/S0140-6736(16)31012-1.
3. Grant WB. Roles of solar UVB and vitamin D in reducing cancer risk and increasing survival. Anticancer Res. 2016;36(3):1357–70.
4. Ma Y, Johnson CS, Trump DL. Mechanistic insights of vitamin D anticancer effects. Vitam Horm. 2016;100:395–431. doi:10.1016/bs.vh.2015.11.003.
5. Dilworth FJ, Scott I, Green A, Strugnell S, Guo YD, Roberts EA, et al. Different mechanisms of hydroxylation site selection by liver and kidney cytochrome P450 species (CYP27 and CYP24) involved in vitamin D metabolism. J Biol Chem. 1995;270(28):16766–74.
6. Guo YD, Strugnell S, Back DW, Jones G. Transfected human liver cytochrome P-450 hydroxylates vitamin D analogs at different side-chain positions. Proc Natl Acad Sci U S A. 1993;90(18):8668–72.
7. McCollum EV. The paths to the discovery of vitamins A and D. J Nutr. 1967;91(2) Suppl 1:11–6.
8. Holick MF, Richtand NM, McNeill SC, Holick SA, Frommer JE, Henley JW, et al. Isolation and identification of previtamin D3 from the skin of rats exposed to ultraviolet irradiation. Biochemistry. 1979;18(6):1003–8.
9. Holick MF, MacLaughlin JA, Clark MB, Holick SA, Potts Jr JT, Anderson RR, et al. Photosynthesis of previtamin D3 in human skin and the physiologic consequences. Science. 1980;210(4466):203–5.
10. Deluca HF. History of the discovery of vitamin D and its active metabolites. Bonekey Rep. 2014;3:479. doi:10.1038/bonekey.2013.213.
11. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer. 2007;7(9):684–700. doi:10.1038/nrc2196.
12. Bouillon R, Carmeliet G, Verlinden L, van Etten E, Verstuyf A, Luderer HF, et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev. 2008;29(6):726–76.
13. Moukayed M, Grant WB. Molecular link between vitamin D and cancer prevention. Nutrition. 2013;5(10):3993–4021. doi:10.3390/nu5103993.
14. Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD, Selznick SH, et al. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res Off J Am Soc Bone Miner Res. 1998;13(3):325–49.
15. Christakos S, Dhawan P, Liu Y, Peng X, Porta A. New insights into the mechanisms of vitamin D action. J Cell Biochem. 2003;88(4):695–705.
16. Zanatta L, Bouraima-Lelong H, Delalande C, Silva FR, Carreau S. Regulation of aromatase expression by 1alpha,25(OH)2 vitamin D3 in rat testicular cells. Reprod Fertil Dev. 2011;23(5):725–35.
17. Rosen CJ, Adams JS, Bikle DD, Black DM, Demay MB, Manson JE, et al. The nonskeletal effects of vitamin D: an Endocrine Society scientific statement. Endocr Rev. 2012;33(3):456–92.
18. Baran DT, Sorensen AM. Rapid actions of 1 alpha-25-dihydroxyvitamin D3 physiologic role. Proc Soc Exp Biol Med. 1994;207(2):175–9.
19. Shi H, Norman AW, Okamura WH, Sen A, Zemel MB. 1alpha,25-dihydroxyvitamin D3 modulates human adipocyte metabolism via nongenomic action. FASEB journal: Official Publication of the Federation of American Societies for Experimental Biology. 2001;15(14):2751–3.
20. Tomlinson IP, Lambros MB, Roylance RR. Loss of heterozygosity analysis: practically and conceptually flawed? Genes Chromosom Cancer. 2002;34(4):349–53.
21. Testa JR, Hino O. Tumor suppressor genes and the two-hit model of recessive oncogenesis: celebrating Alfred Knudson's 80th birthday. Genes Chromosom Cancer. 2003;38(4):286–7.
22. Diaz-Cano SJ. Pathological bases for a robust application of cancer molecular classification. Int J Mol Sci. 2015;16(4):8655–75. doi:10.3390/ijms16048655.
23. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer. 1997;33(5):787–91.
24. Takeishi S, Nakayama KI. To wake up cancer stem cells, or to let them sleep, that is the question. Cancer Sci. 2016;107(7):875–81.
25. Lopez-Bertoni H, Li Y, Laterra J. Cancer stem cells: dynamic entities in an ever-evolving paradigm. Biol Med (Aligarh). 2015;7(Suppl 2):pii: 001.
26. Maruthanila VL, Elancheran R, Kunnumakkara AB, Kabilan S, Kotoky J. Recent development of targeted approaches for the treatment of breast cancer. Breast Cancer. 2016. doi:10.1007/s12282-016-0732-1.
27. Rani V, Deep G, Singh RK, Palle K, Yadav UC. Oxidative stress and metabolic disorders: pathogenesis and therapeutic strategies. Life Sci. 2016;148:183–93.
28. Adorno-Cruz V, Kibria G, Liu X, Doherty M, Junk DJ, Guan D, et al. Cancer stem cells: targeting the roots of cancer, seeds of metastasis, and sources of therapy resistance. Cancer Res. 2015;75(6):924–9.
29. Gudkov AV, Komarova EA. p53 and the Carcinogenicity of Chronic Inflammation. Cold Spring Harbor Perspectives in Medicine. 2016;6(11). doi:10.1101/cshperspect.a026161.
30. Grant WB. MM. Role of ultraviolet-B irradiance and vitamin D in reducing risk of cancer. In: Suba Z, editor. Recent avenues to cancer prevention. N.Y.: Nova Science Publishers, Inc.; 2014.
31. Swami S, Krishnan AV, Feldman D. 1alpha,25-dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells. Clin Cancer Res: An Official Journal of the American Association for Cancer Research. 2000;6(8):3371–9.
32. Swami S, Raghavachari N, Muller UR, Bao YP, Feldman D. Vitamin D growth inhibition of breast cancer cells: gene expression patterns assessed by cDNA microarray. Breast Cancer Res Treat. 2003;80(1):49–62.
33. Krishnan AV, Swami S, Feldman D. Vitamin D and breast cancer: inhibition of estrogen synthesis and signaling. J Steroid Biochem Mol Biol. 2010;121(1–2):343–8.
34. Krishnan AV, Swami S, Peng L, Wang J, Moreno J, Feldman D. Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy. Endocrinology. 2010;151(1):32–42. doi:10.1210/en.2009-0855.
35. Chiang KC, Yeh CN, Chen SC, Shen SC, Hsu JT, Yeh TS, et al. MART-10, a new generation of vitamin D analog, is more potent than 1alpha,25-dihydroxyvitamin D(3) in inhibiting cell proliferation and inducing apoptosis in ER+ MCF-7 breast cancer cells. Evid Based Complement Alternat Med: eCAM. 2012;2012:310872.
36. Richards SE, Weierstahl KA, Kelts JL. Vitamin D effect on growth and vitamin D metabolizing enzymes in triple-negative breast cancer. Anticancer Res. 2015;35(2):805–10.
37. Mercier T, Chaumontet C, Gaillard-Sanchez I, Martel P, Heberden C. Calcitriol and lexicalcitol (KH1060) inhibit the growth of human breast adenocarcinoma cells by enhancing transforming growth factor-beta production. Biochem Pharmacol. 1996;52(3):505–10.
38. Yanagisawa J, Yanagi Y, Masuhiro Y, Suzawa M, Watanabe M, Kashiwagi K, et al. Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators. Science. 1999;283(5406):1317–21.
39. Verlinden L, Verstuyf A, Convents R, Marcelis S, Van Camp M, Bouillon R. Action of 1,25(OH)2D3 on the cell cycle genes, cyclin D1, p21 and p27 in MCF-7 cells. Mol Cell Endocrinol. 1998;142(1–2):57–65.
40. Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE. 1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res. 2000;87(3):214–20.
41. Swami S, Krishnan AV, Wang JY, Jensen K, Horst R, Albertelli MA, et al. Dietary vitamin D(3) and 1,25-dihydroxyvitamin D(3) (calcitriol) exhibit equivalent anticancer activity in mouse xenograft models of breast and prostate cancer. Endocrinology. 2012;153(6):2576–87.
42. Jeong Y, Swami S, Krishnan AV, Williams JD, Martin S, Horst RL, et al. Inhibition of mouse breast tumor-initiating cells by calcitriol and dietary vitamin D. Mol Cancer Ther. 2015;14(8):1951–61.
43. Wahler J, So JY, Cheng LC, Maehr H, Uskokovic M, Suh N. Vitamin D compounds reduce mammosphere formation and decrease expression of putative stem cell markers in breast cancer. J Steroid Biochem Mol Biol. 2015;148:148–55.
44. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7.
45. Clevers H. At the crossroads of inflammation and cancer. Cell. 2004;118(6):671–4.
46. Rakoff-Nahoum S. Why cancer and inflammation? Yale J Biol Med. 2006;79(3–4):123–30.
47. Omrane I, Benammar-Elgaaied A. The immune microenvironment of the colorectal tumor: involvement of immunity genes and microRNAs belonging to the TH17 pathway. Biochim Biophys Acta. 2015;1856(1):28–38.
48. Wang K, Karin M. Tumor-elicited inflammation and colorectal cancer. Adv Cancer Res. 2015;128:173–96.
49. West AC, Jenkins BJ. Inflammatory and non-inflammatory roles for toll-like receptors in gastrointestinal cancer. Curr Pharm Des. 2015;21(21):2968–77.
50. Zhao JL, Xiao CX, Guleng B. Immunopathogenesis of colitis-associated cancer in an animal model. Crit Rev Eukaryot Gene Expr. 2015;25(3):245–51.
51. Bao BY, Yao J, Lee YF. 1alpha, 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis. 2006;27(9):1883–93.
52. Kovalenko PL, Zhang Z, Cui M, Clinton SK, Fleet JC. 1,25 dihydroxyvitamin D-mediated orchestration of anticancer, transcript-level effects in the immortalized, non-transformed prostate epithelial cell line, RWPE1. BMC Genomics. 2010;11:26.
53. Kaler P, Augenlicht L, Klampfer L. Macrophage-derived IL-1beta stimulates Wnt signaling and growth of colon cancer cells: a crosstalk interrupted by vitamin D3. Oncogene. 2009;28(44):3892–902.
54. Brabletz T, Jung A, Kirchner T. Beta-catenin and the morphogenesis of colorectal cancer. Virchows Arch. 2002;441(1):1–11.
55. Hadjihannas MV, Bruckner M, Jerchow B, Birchmeier W, Dietmaier W, Behrens J. Aberrant Wnt/beta-catenin signaling can induce chromosomal instability in colon cancer. Proc Natl Acad Sci U S A. 2006;103(28):10747–52.
56. Fodde R, Brabletz T. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol. 2007;19(2):150–8.
57. Aguilera O, Pena C, Garcia JM, Larriba MJ, Ordonez-Moran P, Navarro D, et al. The Wnt antagonist DICKKOPF-1 gene is induced by 1alpha,25-dihydroxyvitamin D3 associated to the differentiation of human colon cancer cells. Carcinogenesis. 2007;28(9):1877–84.
58. Subramaniam N, Leong GM, Cock TA, Flanagan JL, Fong C, Eisman JA, et al. Cross-talk between 1,25-dihydroxyvitamin D3 and transforming growth factor-beta signaling requires binding of VDR and Smad3 proteins to their cognate DNA recognition elements. J Biol Chem. 2001;276(19):15741–6.
59. Lyakh LA, Sanford M, Chekol S, Young HA, Roberts AB. TGF-beta and vitamin D3 utilize distinct pathways to suppress IL-12 production and modulate rapid differentiation of human monocytes into CD83+ dendritic cells. J Immunol. 2005;174(4):2061–70.
60. Ruemmele FM, Garnier-Lengline H. Transforming growth factor and intestinal inflammation: the role of nutrition. Nestle Nutr Inst Workshop Ser. 2013;77:91–8.
61. Chen A, Davis BH, Sitrin MD, Brasitus TA, Bissonnette M. Transforming growth factor-beta 1 signaling contributes to Caco-2 cell growth inhibition induced by 1,25(OH)(2)D(3). Am J Physiol Gastrointest Liver Physiol. 2002;283(4):G864–74.
62. Chen S, Zhu J, Zuo S, Ma J, Zhang J, Chen G, et al. 1,25(OH)2D3 attenuates TGF-beta1/beta2-induced increased migration and invasion via inhibiting epithelial-mesenchymal transition in colon cancer cells. Biochem Biophys Res Commun. 2015;468(1–2):130–5. doi:10.1016/j.bbrc.2015.10.146.
63. Tong WM, Hofer H, Ellinger A, Peterlik M, Cross HS. Mechanism of antimitogenic action of vitamin D in human colon carcinoma cells: relevance for suppression of epidermal growth factor-stimulated cell growth. Oncol Res. 1999;11(2):77–84.
64. Diaz GD, Paraskeva C, Thomas MG, Binderup L, Hague A. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Cancer Res. 2000;60(8):2304–12.
65. Srinivasan M, Parwani AV, Hershberger PA, Lenzner DE, Weissfeld JL. Nuclear vitamin D receptor expression is associated with improved survival in non-small cell lung cancer. J Steroid Biochem Mol Biol. 2011;123(1–2):30–6.
66. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med. 2002;8(8):816–24.
67. Anderson MG, Nakane M, Ruan X, Kroeger PE, Wu-Wong JR. Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother Pharmacol. 2006;57(2):234–40.
68. Parise RA, Egorin MJ, Kanterewicz B, Taimi M, Petkovich M, Lew AM, et al. CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer. Int J Cancer. 2006;119(8):1819–28.
69. Chen G, Kim SH, King AN, Zhao L, Simpson RU, Christensen PJ, et al. CYP24A1 is an independent prognostic marker of survival in patients with lung adenocarcinoma. Clin Cancer Res: An Official Journal of the American Association for Cancer Research. 2011;17(4):817–26.
70. Zhang Q, Kanterewicz B, Buch S, Petkovich M, Parise R, Beumer J, et al. CYP24 inhibition preserves 1alpha,25-dihydroxyvitamin D(3) anti-proliferative signaling in lung cancer cells. Mol Cell Endocrinol. 2012;355(1):153–61.
71. Shay JW, Werbin H, Wright WE. Telomerase assays in the diagnosis and prognosis of cancer. CIBA Found Symp. 1997;211:148–55. discussion 55-9
72. Blackburn EH. Telomeres and telomerase: their mechanisms of action and the effects of altering their functions. FEBS Lett. 2005;579(4):859–62.
73. Kasiappan R, Shen Z, Tse AK, Jinwal U, Tang J, Lungchukiet P, et al. 1,25-dihydroxyvitamin D3 suppresses telomerase expression and human cancer growth through microRNA-498. J Biol Chem. 2012;287(49):41297–309.
74. Jiang F, Bao J, Li P, Nicosia SV, Bai W. Induction of ovarian cancer cell apoptosis by 1,25-dihydroxyvitamin D3 through the down-regulation of telomerase. J Biol Chem. 2004;279(51):53213–21.
75. Jiang F, Li P, Fornace Jr AJ, Nicosia SV, Bai W. G2/M arrest by 1,25-dihydroxyvitamin D3 in ovarian cancer cells mediated through the induction of GADD45 via an exonic enhancer. J Biol Chem. 2003;278(48):48030–40.
76. Ahonen MH, Zhuang YH, Aine R, Ylikomi T, Tuohimaa P. Androgen receptor and vitamin D receptor in human ovarian cancer: growth stimulation and inhibition by ligands. Int J Cancer. 2000;86(1):40–6.
77. Hummel D, Aggarwal A, Borka K, Bajna E, Kallay E, Horvath HC. The vitamin D system is deregulated in pancreatic diseases. J Steroid Biochem Mol Biol. 2014;144 Pt B:402–409.
78. Mathew R, Kongara S, Beaudoin B, Karp CM, Bray K, Degenhardt K, et al. Autophagy suppresses tumor progression by limiting chromosomal instability. Genes Dev. 2007;21(11):1367–81.
79. Karantza-Wadsworth V, Patel S, Kravchuk O, Chen G, Mathew R, Jin S, et al. Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. Genes Dev. 2007;21(13):1621–35.
80. Wang J, Lian H, Zhao Y, Kauss MA, Spindel S. Vitamin D3 induces autophagy of human myeloid leukemia cells. J Biol Chem. 2008;283(37):25596–605.
81. Albertson DG, Ylstra B, Segraves R, Collins C, Dairkee SH, Kowbel D, et al. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet. 2000;25(2):144–6. doi:10.1038/75985.
82. Mimori K, Tanaka Y, Yoshinaga K, Masuda T, Yamashita K, Okamoto M, et al. Clinical significance of the overexpression of the candidate oncogene CYP24 in esophageal cancer. Ann Oncol: Official Journal of the European Society for Medical Oncology / ESMO. 2004;15(2):236–41.
83. Hobaus J, Thiem U, Hummel DM, Kallay E. Role of calcium, vitamin D, and the extrarenal vitamin D hydroxylases in carcinogenesis. Anti Cancer Agents Med Chem. 2013;13(1):20–35.
84. Ikeda N, Uemura H, Ishiguro H, Hori M, Hosaka M, Kyo S, et al. Combination treatment with 1alpha,25-dihydroxyvitamin D3 and 9-cis-retinoic acid directly inhibits human telomerase reverse transcriptase transcription in prostate cancer cells. Mol Cancer Ther. 2003;2(8):739–46.
85. Hisatake J, Kubota T, Hisatake Y, Uskokovic M, Tomoyasu S, Koeffler HP. 5,6-trans-16-ene-vitamin D3: a new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells. Cancer Res. 1999;59(16):4023–9.
86. Chiang KC, Yeh CN, Hsu JT, Chen LW, Kuo SF, Sun CC, et al. MART-10, a novel vitamin D analog, inhibits head and neck squamous carcinoma cells growth through cell cycle arrest at G0/G1 with upregulation of p21 and p27 and downregulation of telomerase. J Steroid Biochem Mol Biol. 2013;138:427–34.
87. Blutt SE, McDonnell TJ, Polek TC, Weigel NL. Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology. 2000;141(1):10–7. doi:10.1210/endo.141.1.7289.
88. Blutt SE, Allegretto EA, Pike JW, Weigel NL. 1,25-dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocrinology. 1997;138(4):1491–7. doi:10.1210/endo.138.4.5063.
89. Zhuang SH, Burnstein KL. Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology. 1998;139(3):1197–207. doi:10.1210/endo.139.3.5770.
90. Rohan JN, Weigel NL. 1Alpha,25-dihydroxyvitamin D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells. Endocrinology. 2009;150(5):2046–54. doi:10.1210/en.2008-1395.
91. Washington MN, Kim JS, Weigel NL. 1alpha,25-dihydroxyvitamin D3 inhibits C4-2 prostate cancer cell growth via a retinoblastoma protein (Rb)-independent G1 arrest. Prostate. 2011;71(1):98–110. doi:10.1002/pros.21226.
92. Deeb KK, Luo W, Karpf AR, Omilian AR, Bshara W, Tian L, et al. Differential vitamin D 24-hydroxylase/CYP24A1 gene promoter methylation in endothelium from benign and malignant human prostate. Epigenetics. 2011;6(8):994–1000.
93. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007;39(1):44–84. doi:10.1016/j.biocel.2006.07.001.
94. Bao BY, Ting HJ, Hsu JW, Lee YF. Protective role of 1 alpha, 25-dihydroxyvitamin D3 against oxidative stress in nonmalignant human prostate epithelial cells. Int J Cancer. 2008;122(12):2699–706. doi:10.1002/ijc.23460.
95. Ben-Shoshan M, Amir S, Dang DT, Dang LH, Weisman Y, Mabjeesh NJ. 1alpha,25-dihydroxyvitamin D3 (calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. Mol Cancer Ther. 2007;6(4):1433–9. doi:10.1158/1535-7163.MCT-06-0677.
96. Chung I, Han G, Seshadri M, Gillard BM, Yu WD, Foster BA, et al. Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. Cancer Res. 2009;69(3):967–75. doi:10.1158/0008-5472.CAN-08-2307.
97. Ray R, Banks M, Abuzahra H, Eddy VJ, Persons KS, Lucia MS, et al. Effect of dietary vitamin D and calcium on the growth of androgen-insensitive human prostate tumor in a murine model. Anticancer Res. 2012;32(3):727–31.
98. Garland CF, Garland FC. Do sunlight and vitamin D reduce the likelihood of colon cancer? Int J Epidemiol. 1980;9(3):227–31.
99. Grant WB. An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer. 2002;94(6):1867–75. doi:10.1002/cncr.10427.
100. Grant WB, Garland CF. The association of solar ultraviolet B (UVB) with reducing risk of cancer: multifactorial ecologic analysis of geographic variation in age-adjusted cancer mortality rates. Anticancer Res. 2006;26(4A):2687–99.
101. Lin SW, Wheeler DC, Park Y, Cahoon EK, Hollenbeck AR, Freedman DM, et al. Prospective study of ultraviolet radiation exposure and risk of cancer in the United States. Int J Cancer. 2012;131(6):E1015–23. doi:10.1002/ijc.27619.
102. Zamoiski RD, Freedman DM, Linet MS, Kitahara CM, Liu W, Cahoon EK. Prospective study of ultraviolet radiation exposure and risk of breast cancer in the United States. Environ Res. 2016;151:419–27. doi:10.1016/j.envres.2016.08.013.
103. Grant WB. Re: prospective study of ultraviolet radiation exposure and risk of breast cancer in the United States. Environ Res. 2017;152(1):517–8
104. Grant WB. 25-hydroxyvitamin D and breast cancer, colorectal cancer, and colorectal adenomas: case-control versus nested case-control studies. Anticancer Res. 2015;35(2):1153–60.
105. Oh EY, Ansell C, Nawaz H, Yang CH, Wood PA, Hrushesky WJ. Global breast cancer seasonality. Breast Cancer Res Treat. 2010;123(1):233–43. doi:10.1007/s10549-009-0676-7.
106. Eliassen AH, Warner ET, Rosner B, Collins LC, Beck AH, Quintana LM, et al. Plasma 25-hydroxyvitamin D and risk of breast cancer in women followed over 20 Years. Cancer Res. 2016;76(18):5423–30. doi:10.1158/0008-5472.CAN-16-0353.
107. Tretli S, Schwartz GG, Torjesen PA, Robsahm TE. Serum levels of 25-hydroxyvitamin D and survival in Norwegian patients with cancer of breast, colon, lung, and lymphoma: a population-based study. Cancer Causes Control. 2012;23(2):363–70. doi:10.1007/s10552-011-9885-6.
108. Yao S, Sucheston LE, Millen AE, Johnson CS, Trump DL, Nesline MK, et al. Pretreatment serum concentrations of 25-hydroxyvitamin D and breast cancer prognostic characteristics: a case-control and a case-series study. PLoS One. 2011;6(2):e17251. doi:10.1371/journal.pone.0017251.
109. Fedirko V, Torres-Mejia G, Ortega-Olvera C, Biessy C, Angeles-Llerenas A, Lazcano-Ponce E, et al. Serum 25-hydroxyvitamin D and risk of breast cancer: results of a large population-based case-control study in Mexican women. Cancer Causes Control. 2012;23(7):1149–62. doi:10.1007/s10552-012-9984-z.
110. Thanasitthichai S, Chaiwerawattana A, Prasitthipayong A. Association of Vitamin D Level with Clinicopathological features in breast cancer. Asian Pac J Cancer Prev. 2015;16(12):4881–3.
111. Haugen J, Chandyo RK, Ulak M, Mathisen M, Basnet S, Brokstad KA, et al. 25-hydroxy-vitamin D concentration is not affected by severe or non-severe pneumonia, or inflammation, in young children. Nutrition. 2017;9(1). doi:10.3390/nu9010052.
112. Bolland MJ, Grey A, Gamble GD, Reid IR. Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women's Health Initiative (WHI) limited-access data set. Am J Clin Nutr. 2011;94(4):1144–9. doi:10.3945/ajcn.111.015032.
113. IARC. Vitamin D and cancer. Lyon: International agency for research on cancer; 2008.
114. Ma Y, Zhang P, Wang F, Yang J, Liu Z, Qin H. Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies. J Clin Oncol: official journal of the American Society of Clinical Oncology. 2011;29(28):3775–82. doi:10.1200/JCO.2011.35.7566.
115. Mohr SB, Gorham ED, Kim J, Hofflich H, Cuomo RE, Garland CF. Could vitamin D sufficiency improve the survival of colorectal cancer patients? J Steroid Biochem Mol Biol. 2015;148:239–44. doi:10.1016/j.jsbmb.2014.12.010.
116. Zgaga L, Theodoratou E, Farrington SM, Din FV, Ooi LY, Glodzik D, et al. Plasma vitamin D concentration influences survival outcome after a diagnosis of colorectal cancer. J Clin Oncol: official journal of the American Society of Clinical Oncology. 2014;32(23):2430–9. doi:10.1200/JCO.2013.54.5947.
117. Chen GC, Zhang ZL, Wan Z, Wang L, Weber P, Eggersdorfer M, et al. Circulating 25-hydroxyvitamin D and risk of lung cancer: a dose-response meta-analysis. Cancer Causes Control. 2015. doi:10.1007/s10552-015-0665-6.
118. Zhang L, Wang S, Che X, Li X. Vitamin D and lung cancer risk: a comprehensive review and meta-analysis. Cell Physiol Biochem. 2015;36(1):299–305. doi:10.1159/000374072.
119. Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis: serum vitamin D and colorectal adenoma risk. Prev Med. 2011;53(1–2):10–6. doi:10.1016/j.ypmed.2011.05.013.
120. Prescott J, Bertrand KA, Poole EM, Rosner BA, Tworoger SS. Surrogates of long-term vitamin d exposure and ovarian cancer risk in two prospective cohort studies. Cancers (Basel). 2013;5(4):1577–600. doi:10.3390/cancers5041577.
121. Tran B, Jordan SJ, Lucas R, Webb PM, Neale R. Association between ambient ultraviolet radiation and risk of epithelial ovarian cancer. Cancer Prev Res (Phila). 2012;5(11):1330–6. doi:10.1158/1940-6207.CAPR-12-0279.
122. Ong JS, Cuellar-Partida G, Lu Y. Ovarian Cancer Study A, Fasching PA, Hein A et al. Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. Int J Epidemiol. 2016. doi:10.1093/ije/dyw207.
123. Wolpin BM, Ng K, Bao Y, Kraft P, Stampfer MJ, Michaud DS, et al. Plasma 25-hydroxyvitamin D and risk of pancreatic cancer. Cancer Epidemiol Biomark Prev: a Publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2012;21(1):82–91. doi:10.1158/1055-9965.EPI-11-0836.
124. Altieri B, Grant WB, Casa SD, Orio F, Pontecorvi A, Colao A, et al. Vitamin D and pancreas: the role of sunshine vitamin in the pathogenesis of diabetes mellitus and pancreatic cancer. Crit Rev Food Sci Nutr. 2016. doi:10.1080/10408398.2015.1136922.
125. Eryilmaz MK, Mutlu H, Gunduz S, Uysal M, Musri FY, Coskun HS. More sunlight exposure may improve the overall survival in patients with pancreas cancer. J Oncol Sci. 2015;2(2–3):73–6.
126. Grant WB. Effect of interval between serum draw and follow-up period on relative risk of cancer incidence with respect to 25-hydroxyvitamin D level: implications for meta-analyses and setting vitamin D guidelines. Dermato-endocrinol. 2011;3(3):199–204. doi:10.4161/derm.3.3.15364.
127. Xu Y, Shao X, Yao Y, Xu L, Chang L, Jiang Z, et al. Positive association between circulating 25-hydroxyvitamin D levels and prostate cancer risk: new findings from an updated meta-analysis. J Cancer Res Clin Oncol. 2014;140(9):1465–77. doi:10.1007/s00432-014-1706-3.
128. Gilbert R, Metcalfe C, Fraser WD, Donovan J, Hamdy F, Neal DE, et al. Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade. Int J Cancer. 2012;131(5):1187–96. doi:10.1002/ijc.27327.
129. Marshall DT, Savage SJ, Garrett-Mayer E, Keane TE, Hollis BW, Horst RL, et al. Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. J Clin Endocrinol Metab. 2012;97(7):2315–24. doi:10.1210/jc.2012-1451.
130. Mondul AM, Weinstein SJ, Moy KA, Mannisto S, Albanes D. Circulating 25-Hydroxyvitamin D and Prostate Cancer Survival. Cancer Epidemiology, Biomarkers & Prevention: a Publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2016. doi:10.1158/1055–9965.EPI-15-0991.
131. Brandstedt J, Almquist M, Ulmert D, Manjer J, Malm J. Vitamin D, PTH, and calcium and tumor aggressiveness in prostate cancer: a prospective nested case-control study. Cancer Causes Control. 2016;27(1):69–80. doi:10.1007/s10552-015-0684-3.
132. Garland C, Shekelle RB, Barrett-Connor E, Criqui MH, Rossof AH, Paul O. Dietary vitamin D and calcium and risk of colorectal cancer: a 19-year prospective study in men. Lancet. 1985;1(8424):307–9.
133. Garland CF, Comstock GW, Garland FC, Helsing KJ, Shaw EK, Gorham ED. Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet. 1989;2(8673):1176–8.
134. Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer. 2011;128(6):1414–24. doi:10.1002/ijc.25439.
135. Rebel H, der Spek CD, Salvatori D, van Leeuwen JP, Robanus-Maandag EC, de Gruijl FR. UV exposure inhibits intestinal tumor growth and progression to malignancy in intestine-specific Apc mutant mice kept on low vitamin D diet. Int J Cancer. 2015;136(2):271–7. doi:10.1002/ijc.29002.
136. Donneyong MM, Taylor KC, Kerber RA, Hornung CA, Scragg R. Is outdoor recreational activity an independent predictor of cardiovascular disease mortality - NHANES III? Nutr Metab Cardiovasc Dis. 2016;26(8):735–42. doi:10.1016/j.numecd.2016.02.008.
137. Giovannucci E, Liu Y, Willett WC. Cancer incidence and mortality and vitamin D in black and white male health professionals. Clin Cancer Res: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2006;15(12):2467–72. doi:10.1158/1055-9965.EPI-06-0357.
138. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr. 2007;85(6):1586–91.
139. Heaney RP. Guidelines for optimizing design and analysis of clinical studies of nutrient effects. Nutr Rev. 2014;72(1):48–54. doi:10.1111/nure.12090.
140. Lappe J, Travers-Gustafon D, Garland C, Heaney R, Recker R, Watson P. Vitamin D3 and calcium supplementation significantly decreases cancer risk in older women. American Public Health Association 2016 meeting; October 31, 2016; Denver, Colorado 2016.
141. Milczarek M, Psurski M, Kutner A, Wietrzyk J. Vitamin D analogs enhance the anticancer activity of 5-fluorouracil in an in vivo mouse colon cancer model. BMC Cancer. 2013;13:294. doi:10.1186/1471-2407-13-294.
142. Milczarek M, Rosinska S, Psurski M, Maciejewska M, Kutner A, Wietrzyk J. Combined colonic cancer treatment with vitamin D analogs and irinotecan or oxaliplatin. Anticancer Res. 2013;33(2):433–44.
143. Milczarek M, Filip-Psurska B, Swietnicki W, Kutner A, Wietrzyk J. Vitamin D analogs combined with 5-fluorouracil in human HT-29 colon cancer treatment. Oncol Rep. 2014;32(2):491–504. doi:10.3892/or.2014.3247.
144. Hershberger PA, Yu WD, Modzelewski RA, Rueger RM, Johnson CS, Trump DL. Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res: An Official Journal of the American Association for Cancer Research. 2001;7(4):1043–51.
145. Koshizuka K, Koike M, Asou H, Cho SK, Stephen T, Rude RK, et al. Combined effect of vitamin D3 analogs and paclitaxel on the growth of MCF-7 breast cancer cells in vivo. Breast Cancer Res Treat. 1999;53(2):113–20.
146. Zeichner SB, Koru-Sengul T, Shah N, Liu Q, Markward NJ, Montero AJ, et al. Improved clinical outcomes associated with vitamin D supplementation during adjuvant chemotherapy in patients with HER2+ nonmetastatic breast cancer. Clin Breast Cancer. 2015;15(1):e1–11. doi:10.1016/j.clbc.2014.08.001.
147. Ma Y, Yu WD, Hershberger PA, Flynn G, Kong RX, Trump DL, et al. 1alpha,25-dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model. Mol Cancer Ther. 2008;7(9):3047–55. doi:10.1158/1535-7163.MCT-08-0243.
148. Hershberger PA, McGuire TF, Yu WD, Zuhowski EG, Schellens JH, Egorin MJ, et al. Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression. Mol Cancer Ther. 2002;1(10):821–9.
149. Refaat B, El-Shemi AG, Kensara OA, Mohamed AM, Idris S, Ahmad J, et al. Vitamin D3 enhances the tumouricidal effects of 5-fluorouracil through multipathway mechanisms in azoxymethane rat model of colon cancer. J Exp Clin Cancer Res: CR. 2015;34:71. doi:10.1186/s13046-015-0187-9.
150. McGuire TF, Trump DL, Johnson CS. Vitamin D(3)-induced apoptosis of murine squamous cell carcinoma cells. Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1. J Biol Chem. 2001;276(28):26365–73. doi:10.1074/jbc.M010101200.